Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increasing-dose salbutamol versus salbutamol plus ipratropium bromide in adults with mild asthma and normal spirometry
IRCT20241229064206N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of salbutamol and ipratropium bromide in asthma (2 arms), sponsored by Kashan University of Medical Sciences. Primary endpoints: Change in spirometric indices, Reducing treatment costs and 1 more. Started Jan 2025; status: completed.
02
Drugs
salbutamolipratropium bromide
03
Conditions
asthma
Beyond the preview
Go deeper on IRCT20241229064206N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241229064206N1.